Earnings Results: Fast start for coronavirus drug boosts Gilead earnings, but stock sinks on forecast
In the first quarter of sales of its COVID-19 antiviral drug, Gilead Sciences Inc. produced better profit and sales than expected, buts its beleaguered shares were hit by a reduction in its annual sales forecast Wednesday.
